Oic Pamora denied as not FDA-approved for this use by Humana?

Humana's specific coverage criteria for oic pamora are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana May Deny a PAMORA for Opioid-Induced Constipation as "Not FDA-Approved"

Peripherally acting mu-opioid receptor antagonists (PAMORAs) are a class of medications designed specifically to relieve opioid-induced constipation (OIC) without reversing pain control. Humana may issue a "not FDA-approved" denial if the specific PAMORA prescribed, the dosage form, or the precise indication as documented does not align with what the plan has verified against the FDA label — or if there is an internal formulary review lag following a newer approval.

### Why This Denial Is Appealable

If the prescribed medication holds an FDA approval for OIC in adults on chronic opioid therapy, the "not FDA-approved" basis is factually incorrect and directly challengeable. Your prescriber should confirm the exact FDA-approved indication language on the current prescribing label and match it to the documented diagnosis in your chart.

### Federal Appeal Framework

• Internal appeal: Submit a first-level internal appeal within the timeframe shown on your denial notice (typically 180 days under ERISA §503 full-and-fair review, or the period your plan specifies under ACA rules).
• External review (ACA §2719): If the internal appeal fails, you have the right to an independent external review. The external-review request window is generally within four months of the final internal denial. An independent review organization (IRO) — not Humana — makes the binding decision.
• Expedited option: If your condition is urgent (severe, refractory OIC impairing your ability to maintain opioid therapy for a serious underlying condition), request an expedited appeal. Expedited external reviews can be resolved within 72 hours.

### Documentation to Gather

1. FDA label confirmation: Print or link the current FDA-approved prescribing information for the specific PAMORA. Highlight the indication section that matches your diagnosis. 2. Diagnosis records: Chart notes confirming OIC diagnosis, duration, and severity, tied to documented ongoing opioid therapy. 3. Prescriber medical-necessity letter: A signed letter from your treating clinician stating that the prescribed agent is FDA-approved for your documented indication and explaining why it is medically necessary. 4. Prior-treatment history: If Humana's denial also implies a formulary alternative exists, document any prior laxative or other OIC treatment attempts with dates and outcomes.

### Criteria-Mapping Approach

Request Humana's current medical policy for PAMORAs in writing. Then build a point-by-point response:

| Policy Requirement | Your Chart Evidence | |---|---| | FDA-approved indication | [Prescriber confirms: exact indication from label matches diagnosis in chart] | | Chronic opioid therapy documented | [Chart dates, prescribing provider, diagnosis] | | Inadequate response to conservative measures (if required) | [Treatment history with dates and outcomes] |

An appeal grounded in the FDA label's own indication language — submitted with a prescriber letter and supporting chart documentation — is one of the strongest arguments available for overturning this type of denial.